ALUMIS INC. (ALMS) earnings date
Mar 17, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 16 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | after close | 43 | 8-K |
| Q2 FY2026 | Thu, Aug 13, 2026 | after close | 44 | 8-K |
| Q1 FY2026 | Thu, May 14, 2026 | after close | 44 | 8-K |
| Q4 FY2025 | Thu, Mar 19, 2026 | after close | 78 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | after close | 44 | 8-K |
| Q2 FY2025 | Wed, Aug 13, 2025 | after close | 44 | 8-K |
| Q1 FY2025 | Wed, May 14, 2025 | after close | 44 | 8-K |
| Q4 FY2024 | Wed, Mar 19, 2025 | after close | 78 | 8-K |
What they guided beta
| Q3 FY2026 | "EX-99.1 2 alms-ex99d1.htm EX-99.1 Exhibit 99.1 Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies – – Alumis remains on track to submit an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in 4Q 2026 – –Announced topline results from the LUMUS Phase 2b " exhibit |
| Q3 FY2026 | "Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. Envudeucitinib: Systemic Lupus Erythematosus (SLE)" exhibit |
| Q3 FY2026 | "Net loss was $94.9 million for the quarter ended September 30, 2026, compared to net loss of $110.8 million for the quarter ended September 30, 2025. Financial Guidance" exhibit |
| Q3 FY2026 | "Based on the Company’s current operating plan, Alumis continues to anticipate that its existing cash, cash equivalents and marketable securities as of September 30, 2026 are sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027. About Alumis Alumis is a late-stage biopharma company developing next-generation targeted therapies with the potential to significantly improve patient health and outcomes across a range of immune-mediated diseases." exhibit |
| Q2 FY2026 | "EX-99.1 2 alms-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements – ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO – – Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in moderate-to-severe plaque psoriasis (PsO) in Q4 2026 – – Potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE anticipated in Q3 2026 – SOUTH SAN FRANCISCO, Calif., August 13, 2026 – Alumi" exhibit |
| Q2 FY2026 | "We remain on track to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 with the goal, if approved, of bringing this new oral treatment option to patients.” “Looking ahead, our main focus is on realizing our two TYK2 pipeline-in-a-pill franchise opportunities.”" exhibit |
| Q2 FY2026 | "Alumis remains on track to submit its New Drug Application to FDA for envudeucitinib in PsO in the fourth quarter of 2026." exhibit |
| Q2 FY2026 | "Alumis anticipates potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE in the third quarter of 2026, a milestone with the potential to open the Type I interferon disease pathway for the TYK2 franchise. TYK2 Franchise and Pipeline Update" exhibit |
| Q2 FY2026 | "Next clinical candidate (new target) o Alumis now expects to initiate a clinical trial for the next clinical candidate in 2027 Second Quarter 2026 Financial Results" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ALMS
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ALMS
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/ALMS/"><img src="https://veritasdata.dev/embed/ALMS.svg" alt="ALMS earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/ALMS/)
Script
<script async src="https://veritasdata.dev/embed/ALMS.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ALMS"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.